Healing Peptides (BPC-157 / TB-500) Titration and Tapering Algorithms
HealthRX.com
No titration or tapering schedule exists for TB-500 or BPC-157
Key numbers
- 3 mg/mLConcentration of the injectable powder FDA reviewed, not a tested human doseSource: fda.gov, as cited Nov 7, 2026
- 16 of 17 patientsPatients reached by phone in the BPC-157 knee injection chart review, which had no control groupSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 5 mg/5 mgStrength of a BPC-157 plus TB-500 product linked to skin and gum darkening, with no way to tell which peptide caused itSource: fda.gov, as cited Nov 7, 2026
At a glance
- Regulatory status / TB-500 is not FDA-approved or on FDA's compounding bulks lists [1][4][5][6]
- Approved dose of TB-500 / None [1]
- Human pharmacokinetic data for TB-500 / None, by any route [1]
- Formulation FDA reviewed / 3 mg/mL lyophilized powder, subcutaneous or intramuscular [1]
- TB-500 reports in FDA's adverse-event database / None through March 26, 2025 [1]
- Sports status / WADA S2.3; prohibited at all times [7]
Is there a titration schedule for TB-500?
No. A titration schedule needs a starting dose, a step interval and a ceiling taken from human dosing, and none exists [1]. The nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for subcutaneous or intramuscular injection, which describes a concentration and a route rather than a tested dose [1]. Animal work suggests subcutaneous or intraperitoneal TB-500 reaches the bloodstream and is broken down into smaller peptides; no animal studies by intramuscular injection were found [1].
Doses from trials of recombinant full-length thymosin beta-4 do not transfer. That protein is 43 amino acids long; TB-500 is a synthetic, N-acetylated 7-amino-acid fragment of it, residues 17 to 23 [1].
What people on Reddit report
Forum posts from one thread about a product combining two healing peptides. The accounts cover timing with meals, how long results took, and whether it worked.
Before a meal, morning time to get it out of the way. There is no time barrier, just 3 a day and you're golden.Read the source discussion
Respect the BPCs timing. It is a miracle in a bottle but you have to understand depending on the injury it'll take time.Read the source discussion
I am recovering from bursitis and arthritis in my shoulders from boxing/overuse. It does the job!Read the source discussion
Honestly, I bought this and it didn't do anything at all for me.Read the source discussion
Is there a tapering protocol?
There is no study of tapering or stopping TB-500, and no human data on dependence, withdrawal or rebound [1].
For BPC-157, a retrospective chart review reports outcomes after intra-articular knee injections, and a review notes that BPC-157 was safe in inflammatory bowel disease clinical trials [2][3]. Neither provides a tested tapering schedule or a dose ladder to step down from. In the chart review, researchers reached 16 of 17 patients by phone: 12 had received BPC-157 alone and four had received BPC-157 plus thymosin beta-4, whose form was not specified [2]. Three of the four in the combination group and 11 of 12 in the BPC-157-only group reported significant improvement [2]. There was no control group and no validated outcome tool [2].
Questions worth asking
What safety information exists?
FDA's stated concern for injectable TB-500 is an immune reaction, potentially amplified by peptide aggregation and impurities; it found no TB-500 immunogenicity or aggregation study and no nonclinical toxicity studies [1]. Its adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and its food and supplement complaint system retrieved two cases about a blended TB-500 and BPC-157 product with no safety assessment [1].
A 40-year-old woman using a 'research purposes only' BPC-157 plus TB-500 (5 mg/5 mg) product subcutaneously twice daily developed widespread skin hyperpigmentation and gum darkening within a week, recurring when she re-tried it two weeks later; because the product held two peptides, FDA said it could not tell which caused it [8].
Regulatory status
TB-500 sits in the 'nominated but withdrawn' table of FDA's safety-risk page, which holds substances previously in category 2 whose nominators withdrew them; it is not in the active category 2 table, and removal was not a safety finding [9]. It is not on FDA's compounding bulks lists [4][5][6]. FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding it, against FDA staff's recommendation; that advice is non-binding and adding it takes formal rulemaking [10][11]. HHS's draft enforcement-discretion policy, filed October 28, 2026, names TB-500 acetate given subcutaneously or intramuscularly and says HHS does not intend enforcement action against certain pharmacies, facilities and physicians meeting its conditions; it is a draft, creates no rights and is not binding [11][12]. Compounded drugs are not FDA-approved [13]. WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times, on the 2026 and 2027 Lists [7][14].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
What is TB-500?
Is TB-500 legal to compound?
What does WADA say about TB-500?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How long should you cycle BPC-157 TB 500?
No standard cycle length has been established for TB-500 or BPC-157, and no study has tested stopping or tapering either one. For BPC-157, a small chart review and a review of inflammatory bowel disease trials report outcomes but do not test a dose or taper schedule. Whether either peptide needs a break is not established.
How much TB500 to take a week?
No established weekly amount exists. TB-500 has no approved dose, and no titration schedule has been set from human dosing. The nomination FDA reviewed described a 3 mg/mL lyophilized powder for subcutaneous or intramuscular injection, which gives a concentration and route, not a tested dose. Doses from trials of full-length thymosin beta-4 do not transfer to TB-500.
References
Show all 15 referencesHide references
- U.S. Food and Drug Administration.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- World Anti-Doping Agency.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- Compounding and the FDA: Questions and Answers | FDA.
- World Anti-Doping Agency.
- Reddit participants. Gorilla Healing TB-500 BPC-157 (r/bpc_157). Accessed 2026-11-10.